

Need By Date: \_\_\_\_\_ Ship To: ☐ Patient ☐ Office ☐ Other \_\_\_\_\_ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address		Address	
City State ZIP		City State ZIP	
Main Phone	Alternate Phone	Phone	Fax
Social Security #		Contact Person	
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI # License #

Clinical Information	
Diagnosis: <input type="checkbox"/> J45.40 Moderate Asthma <input type="checkbox"/> J45.50 Severe Asthma <input type="checkbox"/> L20.9 Atopic Dermatitis <input type="checkbox"/> L50.1 Chronic Idiopathic Urticaria (CIU) <input type="checkbox"/> J33 Chronic Rhinosinusitis with Nasal Polyposis <input type="checkbox"/> Other: _____ Dx Code: _____	Eosinophil Levels
Concomitant Therapies: <input type="checkbox"/> Short-acting Beta Agonist <input type="checkbox"/> Long-acting Beta Agonist <input type="checkbox"/> Antihistamines <input type="checkbox"/> Decongestants <input type="checkbox"/> Immunotherapy <input type="checkbox"/> Inhaled Corticosteroid <input type="checkbox"/> Leukotriene Modifiers <input type="checkbox"/> Oral Steroids <input type="checkbox"/> Nasal Steroids <input type="checkbox"/> Other: _____	
Please List Therapies	Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs Date Weight Obtained
Lab Results: <input type="checkbox"/> History of positive skin OR RAST test to a perennial aeroallergen Pretreatment Serum IgE Level: _____ IU per mL Test Date: _____ / _____ / _____	
MD Specialty: <input type="checkbox"/> Allergist <input type="checkbox"/> Dermatologist <input type="checkbox"/> ENT <input type="checkbox"/> Pediatrician <input type="checkbox"/> Primary Care <input type="checkbox"/> Pulmonologist <input type="checkbox"/> Other: _____	Prescription Type: <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Restart <input type="checkbox"/> Continued Therapy Last Injection Date: _____ / _____ / _____
Drug Allergies	Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Prescription Information		Qty	Refills	
<input type="checkbox"/> Dupixent®	200 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS w/Shield <input type="checkbox"/> Asthma <input type="checkbox"/> Atopic Dermatitis 300 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS w/Shield <input type="checkbox"/> Asthma <input type="checkbox"/> Atopic Dermatitis 300 mg <input type="checkbox"/> Pen <input type="checkbox"/> PFS w/Shield <input type="checkbox"/> Chronic Rhinosinusitis with Nasal Polyposis	<input type="checkbox"/> Load: Inject 400 mg (as two-200 mg injections in different sites) on Day 1, then inject 200 mg every other week starting on Day 15 <input type="checkbox"/> Maintenance: Inject 200 mg SUBQ every other week <input type="checkbox"/> Load: Inject 600 mg (as two-300 mg injections in different sites) on Day 1, then inject 300 mg every other week starting on Day 15 <input type="checkbox"/> Maintenance: Inject 300 mg SUBQ every other week Inject 300 mg SUBQ every other week	2 Syringes 2 Syringes 2 Syringes 2 Syringes	None _____ None _____ _____
<input type="checkbox"/> Fasenra®	Fax completed Fasenra Access 360™ Enrollment Form to BioPlus Specialty Pharmacy at 800-269-5493			
<input type="checkbox"/> Nucala®	<input type="checkbox"/> 100 mg Pre-filled Auto-injector <input type="checkbox"/> 100 mg PFS <input type="checkbox"/> 100 mg Vial* *Supplies dispensed: One 10 mL vial sterile water for injection for every Nucala vial dispensed, alcohol swabs, 3 mL Luer Lock inj syringe, 21 G NDL for reconstitution, 1 mL polypropylene syringe with 21 G x 1/2" NDL for subcutaneous injection <input type="checkbox"/> No supplies requested (supplies will be sent with shipment unless indicated)	<input type="checkbox"/> Patients with Asthma Inject 100 mg SUBQ once every 4 weeks <input type="checkbox"/> Patients with EGPA Inject 300 mg (3-100 mg injections) SUBQ once every 4 weeks	28 Day Supply 28 Day Supply	_____ _____
<input type="checkbox"/> Xolair®	75 mg <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector 150 mg <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector <input type="checkbox"/> Vial* 300 mg <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjector *Supplies dispensed: One 10 mL sterile water for injection for every Xolair vial dispensed, alcohol swabs, 3 mL Luer Lock inj syringe, 18 G x 1 1/2" Safety Glide NDL for reconstitution, 25 G x 5/8" Safety Glide NDL for subcutaneous injection <input type="checkbox"/> No supplies requested (supplies will be sent with shipment unless indicated)	<b>Patients with Asthma</b> <input type="checkbox"/> Inject 75 mg SUBQ once every 4 weeks <input type="checkbox"/> Inject 150 mg SUBQ once every 4 weeks <input type="checkbox"/> Inject 225 mg SUBQ once every 2 weeks <input type="checkbox"/> Inject 225 mg SUBQ once every 4 weeks <input type="checkbox"/> Inject 300 mg SUBQ once every 2 weeks <input type="checkbox"/> Inject 300 mg SUBQ once every 4 weeks <input type="checkbox"/> Inject 375 mg SUBQ once every 2 weeks <b>Patients with CIU</b> <input type="checkbox"/> Inject 150 mg SUBQ once every 4 weeks <input type="checkbox"/> Inject 300 mg SUBQ once every 4 weeks	28 Day Supply	_____
<input type="checkbox"/> EpiPen® (Injection)	0.3 mg/0.3 mL Pre-filled Auto-injector	Inject EpiPen® 0.3 mg intramuscularly or SUBQ in patients greater than or equal to 30 kg (66 lbs)	2	0
<input type="checkbox"/> EpiPen® Jr (Injection)	0.15 mg/0.3 mL Pre-filled Auto-injector	Inject EpiPen® Jr 0.15 mg intramuscularly or SUBQ in patients 15 to 30 kg (33 lbs to 66 lbs)	2	0
<input type="checkbox"/> Other				

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date